Canterbury DHB

Context

Further Reading

  1. Rumi E, et al. (2017). Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 129:680-692.
  2. Vannucchi AM, et al. (2014). Mutation enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM and IWG-MRT Project. Blood;124:405.
  3. Verstovsek S, et al. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799.
  4. Kröger N, et al. (2015). Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29(11):2126. Epub 2015 Aug 21.
  5. Bacigalupo AM, et al. (2010). Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 45(3): 458-63.
  6. Barbui T, et al. (2018). The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018 Feb 9;8(2):15.
  7. Gangat N, et al. (2011). DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol.;29(4):392.
  8. Ianotto JC, et al. (2017). Benefits and pitfalls of Peg-Interferon-2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis, a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica 181297. Epub ahead of print.
  9. Kröger N, et al. (2015). Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015 May;125(21):3347-50. Epub 2015 Mar 17.
  10. Kröger N. et al. (2017). Impact of Molecular Genetics on Outcome in Myelopfibrosis Patients after Allogenetic Stem Cell Transplantation. Biol Blood Marrow Transplant 23 (2017) 1095–1101.
  11. McLornan DP, et al. (2012). Allogeneic stem cell transplantation for myelofibrosis in 2012. Br J Haematol 157(4): 413-425.
  12. Palmer J, et al. (2017). Transplantation in Myelofibrosis Reaches the Molecular Age. Biol Blood Marrow Transplant 23 1043–1045.
  13. Reilly JT, et al. (2012). Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 158(4): 453-471.
  14. Tefferi A, et al. (2012). One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc 87(1): 25-33.
  15. Tefferi A (2013). Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 88(2): 141-150.
  16. Zang DY, Deeg HJ (2009). Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Current Opinion in Hematology 16(2): 140-146 10.1097/MOH.0b013e3283257ab2.

About this Canterbury DHB document (536551):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

August 2018

Next Review:

April 2021

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 536551